Riverwater Partners LLC cut its stake in shares of Iradimed Corporation (NASDAQ:IRMD – Free Report) by 4.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,119 shares of the medical equipment provider’s stock after selling 506 shares during the period. Riverwater Partners LLC’s holdings in Iradimed were worth $502,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of IRMD. 1620 Investment Advisors Inc. acquired a new stake in Iradimed during the 2nd quarter worth approximately $25,000. Isthmus Partners LLC lifted its holdings in shares of Iradimed by 1.1% during the second quarter. Isthmus Partners LLC now owns 72,664 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 759 shares in the last quarter. Comerica Bank boosted its position in shares of Iradimed by 2,151.6% in the first quarter. Comerica Bank now owns 1,441 shares of the medical equipment provider’s stock valued at $63,000 after acquiring an additional 1,377 shares during the period. SG Americas Securities LLC acquired a new position in shares of Iradimed in the third quarter valued at about $147,000. Finally, EntryPoint Capital LLC bought a new position in Iradimed during the first quarter worth about $150,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.
Iradimed Price Performance
Shares of NASDAQ IRMD opened at $50.49 on Thursday. The business has a fifty day moving average price of $48.13 and a two-hundred day moving average price of $45.10. The stock has a market capitalization of $639.41 million, a PE ratio of 35.81 and a beta of 0.79. Iradimed Corporation has a fifty-two week low of $38.53 and a fifty-two week high of $52.45.
Iradimed Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Tuesday, August 20th were paid a $0.15 dividend. The ex-dividend date was Tuesday, August 20th. This represents a $0.60 annualized dividend and a dividend yield of 1.19%. Iradimed’s payout ratio is 42.55%.
Wall Street Analysts Forecast Growth
Separately, Roth Mkm cut their price objective on shares of Iradimed from $65.00 to $60.00 and set a “buy” rating for the company in a report on Friday, August 2nd.
Check Out Our Latest Stock Analysis on Iradimed
Iradimed Profile
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
Recommended Stories
- Five stocks we like better than Iradimed
- Compound Interest and Why It Matters When Investing
- CrowdStrike Sees Unusual Call Option Surge: What’s Next?
- What Are Dividend Achievers? An Introduction
- GM Stock Is Crushing the Competition in 2024 – Is It Time to Buy?
- 3 Warren Buffett Stocks to Buy Now
- The Nuclear Shift: 3 Best Uranium ETFs to Invest in for 2024
Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iradimed Corporation (NASDAQ:IRMD – Free Report).
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.